trimetrexate has been researched along with Carcinoma, Bronchial in 1 studies
Trimetrexate: A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against PNEUMOCYSTIS PNEUMONIA in AIDS patients. Myelosuppression is its dose-limiting toxic effect.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fossella, FV | 1 |
| Winn, RJ | 1 |
| Holoye, PY | 1 |
| Hallinan, B | 1 |
| Raber, MN | 1 |
| Hoelzer, K | 1 |
| Young, JA | 1 |
| Readling, J | 1 |
| Bowers, B | 1 |
| Hong, WK | 1 |
1 trial available for trimetrexate and Carcinoma, Bronchial
| Article | Year |
|---|---|
Phase II trial of trimetrexate for unresectable or metastatic non-small cell bronchogenic carcinoma.
Topics: Adult; Aged; Carcinoma, Bronchogenic; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; | 1992 |